SavedAdd your journal

Journals / Turkish Neurosurgery / 2016 / Cilt: 26 - Sayı: 3

Transplantation of Neural Precursor Cells in the Treatment of Parkinson’s Disease: An Efficacy and Safety Analysis

Leng LIGE
Tian ZENGMIN
Pages
378–383
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Transplantation of neural precursor cells may be a valid and safe treatment method for Parkinson’s Disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: The aim of this study was to evaluate the clinical safety, feasibility and efficacy of transplantation of neural precursor cells (NPCs) in the treatment for Parkinson’s disease (PD).
📊
Key Findings & Data:MATERIAL and METHODS: Twenty-one patients, aged 42-79 years (median age 57.33 years), participated in the study.
💡
Conclusion & Impact:CONCLUSION: Transplantation of neural precursor cells may be a valid and safe treatment method for Parkinson’s Disease
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: The aim of this study was to evaluate the clinical safety, feasibility and efficacy of transplantation of neural precursor cells (NPCs) in the treatment for Parkinson’s disease (PD). MATERIAL and METHODS: Twenty-one patients, aged 42-79 years (median age 57.33 years), participated in the study. A total of 3 × 107 NPCs in 0.25 ml were deposited unilaterally into the striatum. To access the effectiveness of first transplantation surgery, comparisons between the resulting pre-first surgery evaluation and pre-second surgery evaluation were made with repeatedmeasures analysis of variance. Unified Parkinson’s Disease Rating Scale (UPDRS), Hoehn-Yahr, PDQ-39 and Schwab-England Scores were used to evaluate the Parkinson patients’ neurofunctions. Four aspects were used to assess the possible side effects of transplantation: a) tumor formation, b) immune rejection and use of immunosuppressant, c) graft induced complication and d) delivery related side effects. RESULTS: This study demonstrated that the symptoms of PD patients were statistically improved after transplantation (P<0.01). There were no obvious side effects of transplantation. CONCLUSION: Transplantation of neural precursor cells may be a valid and safe treatment method for Parkinson’s Disease

🔖

Cite This Article

LIGE, L., ZENGMIN, T. (2016). Transplantation of Neural Precursor Cells in the Treatment of Parkinson’s Disease: An Efficacy and Safety Analysis. Turkish Neurosurgery, Cilt: 26 - Sayı: 3, 378–383. https://ajindex.com/articles/404679

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M,Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G: Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6:e1000029, 2009 2. Annett LE: Functional studies of neural grafts in parkinsonian primates. In: Dunnett SB, Bjorklund A (eds), Functional Neural Transplantation. New York: Raven Press, 1994:71–102 3. Arnhold S, Lenartz D, Kruttwig K, Klinz FJ, Kolossov E: Differentiation of green fluorescent protein-labeled embryonic stem cell-derived neural precursor cells into Thy-1-positive neurons and glia after transplantation into adult rat striatum. J Neurosurg 93: 1026–1032, 2000 4. Brustle O, Jones KN, Learish RD, Karram K, Choudhary K: Embryonic stem cell-derived glial precursors: A source of myelinating transplants. Science 285:754–756, 1999 5. Camp DM, Loeffler DA, Farrah DM, Borneman JN, LeWitt PA: Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson’s disease. J Neuroinflammation 6:17, 2009 6. Defer GL, Geny C, Ricolfi F: Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 119:41–50, 1996 7. Duan WM, Widner H, Brundin P, Brundin P: Sequential intrastriatal grafting of allogeneic embryonic dopaminerich neuronal tissue in adult rats; will the second graft be rejected? Neuroscience 57: 261–274, 1993 8. Erdo F, Buhrle C, Blunk J, Hoehn M, Xia Y: Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 23:780–785, 2003 9. Finneman SC, Boulan E: Macrophage and retinal pigment epithelium phagocytosis apoptotic cells and photo receptors compete for AV B3 and AV B5 integrins, and protein kinase C regulates AV B5 binding and cytoskeletal linkage. J Exp Med 190:861–874, 1990 10. Freed CR, Greene PE, Breeze RE: Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344:710–719, 2001 11. Jeanne AP: Prospect of cell therapy for Parkinson’s disease. Anat Cell Biol 44: 256-264, 2011 12. Lindvall O, Kokaia Z: Stem cells for the treatment of neurological disorders. Nature 441: 1094–1096, 2006 13. Lindvall O, Kokaia Z, Martinez-Serrano A: Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 10 Suppl: S42–50, 2004 14. Politis M: Dyskinesias after neural transpla